EC Number   |
Title |
Organism |
|---|
   3.4.21.22 | Development of a novel tricyclic class of potent and selective FIXa inhibitors |
Homo sapiens |
| 3.4.21.22 | Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors |
Homo sapiens |
| 3.4.21.22 | Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity |
Homo sapiens |
| 3.4.21.22 | Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity |
Homo sapiens |
| 3.4.21.22 | Releasing the brakes in coagulation factor IXa by co-operative maturation of the substrate-binding site |
Homo sapiens |
| 3.4.21.22 | 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa |
Homo sapiens |
| 3.4.21.22 | 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa |
Homo sapiens |
| 3.4.21.22 | A sequential mechanism for exosite-mediated factor IX activation by factor XIa |
Homo sapiens |
| 3.4.21.22 | A study of the expression of functional human coagulation factor IX in keratinocytes using a nonviral vector regulated by K14 promoter |
Homo sapiens |
| 3.4.21.22 | A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX |
Homo sapiens |
